G2-phase arrest through p21(WAF1/Cip1) induction and cdc2 repression by gnidimacrin in human hepatoma HLE cells

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1349-1354

  Yoshida, Mitsuzi ^a   Matsui, Yuki ^a   Iizuka, Akira ^a   Ikarashi, Yoshinori ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

Cdc2; E2F 4; G2 phase arrest; Gnidimacrin; P21(wafl cipl); Pkc ii

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE INHIBITOR 1; GNIDIMACRIN; NSC 252940; PROTEIN KINASE C; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; CDC2 PROTEIN, HUMAN; CDKN1A PROTEIN, HUMAN; CYCLIN B; CYCLIN DEPENDENT KINASE INHIBITOR 1A; DITERPENE; MESSENGER RNA; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL GROWTH; CELL NUCLEUS; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME REPRESSION; GENETIC TRANSFECTION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; CELL PROLIFERATION; DRUG EFFECT; FLOW CYTOMETRY; GENETICS; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CYCLIN B; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DITERPENES; FLOW CYTOMETRY; G2 PHASE; HUMANS; LIVER NEOPLASMS; REACTIVE OXYGEN SPECIES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 64949084842     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. 1Yoshida M, Feng W, Saijo N and Ikekawa T: Antitumor activity of daphnane-type diterpene gnidimacrin isolated from Stellera chamaejasme L. Int J Cancer 66: 268-273, 1996.
2. Yoshida M, Yokokura H, Hidaka H, Ikekawa T and Saijo N: Mechanism of antitumor action of PKC activator, gnidimacrin. Int J Cancer 77: 243-250, 1998.
3. Yoshida M, Feng W, Nishio K, Takahashi M, Heike Y, Saijo N, Wakasugi H and Ikekawa T: Antitumor action of the PKC activator gnidimacrin through cdk2 inhibition. Int J Cancer 94: 348-352,2001.
4. Pu H, Tsuji T, Kondo A, Fushimi K, Ohashi R, Inoue Y, Mimura T, Hamazaki K, Miyazaki M and Namba M: Comparison of cellular characteristics between human hepatoma cell lines with wild-type p53 and those with mutant-type p53 gene. Acta Medica Okayamai/: 313-319, 1997.
5. Yoshida M, Heike Y, Ohno S, Ikekawa T and Wakasugi H: Involvement of PKC [β in anti-proliferating action of a new antitumor compound gnidimacrin. Int. J. Cancer 105: 601-606, 2003.
6. Furukawa Y, Iwase S, Terui Y, Kikuchi J, Sakai T, Nakamura M, Kitagawa S and Kitagawa M: Transcriptional activation of the cdc2 gene is associated with Fas-induced apoptosis of human hematopoietic cells. JBC 271: 28469-28477, 1996.
7. Cip1 pathway. JBC 280: 1112-1122, 2005.
8. waf1/cip1 promoter by Sp1. Cancer Res 64: 743-750, 2004.
9. 9Taylor WR, Schonthal AH, Galante J and Stark GR: p 130/E2F4 binds to and represses the cdc2 promoter in response to p53. JBC 276: 1998-2006,2001.
10. 2/M transcription. EMBO J 23: 4615-4626, 2004.
11. Nishizuka Y: The role of protein kinase C in cell surface signal transduction and tumor promotion. Nature 308: 693-698, 1984.
12. Dicker P and Rozengurt E: Stimulation of DNA synthesis by tumor promoter and pure mitogenic factors. Nature 276: 723- 726,1978.
13. Collins MKL and Rozengurt E: Binding of phorbol esters to high-affinity sites on murine fibroblastic cells elicits a mitogenic response. J Cell Physiol 112: 42-50, 1982.
14. Rozengurt E: Early signals in the mitogenic response. Science 234: 161-166, 1986.
15. Choi PM, Tchou-Wong KM and Weinstein IB: Overexpression of protein kinase C in HT29 colon cancer cells cause growth inhibition and tumor suppression. Mol Cell Biol 10: 4650-4657, 1990.
16. Nishio K, Sugimoto Y, Nakagawa K, Niimi S, Fujiwara Y, Bungo M, Kasahara K, Fujiki H and Saijo N: TPA and okadaic acid with tumor promoting activity inhibit the growth of K562, PC9 cells. Br J Cancer 62: 415-419, 1990.
17. Rogalsky V, Todorov G, Den T and Ohnuma T: Increase in protein kinase C activity is associated with human fibroblast growth inhibition. FEBS Lett 304: 153-156, 1992.
18. Powell MB, Rosenberg RK, Graham MJ, Birch ML, Yamanishi DT, Buckmeier JA and Meyskens FL Jr: Protein kinase C β expression in melanoma cells and melanocytes: differential expression correlates with biological responses to 12-0- tetradecanoylphorbol 13-acetate. J Cancer Res Clin Oncol 119: 199-206, 1993.
19. Asiedu C, Biggs J, Lilly M and Kraft AS: Inhibition of leukemic cell growth by the protein kinase C activator bryostatin 1 correlates with the dephosphorylation of cyclin-dependent kinase 2. Cancer Res 55: 3716-3720,1995.
20. Blagosklonny MV, Prabhu NS and El-Deiry WS: Defects in p21 WAFI/Cip1 Rb,and c-myc signaling in phorbol ester-resistant cancer cells. Cancer Res 57: 320-325, 1997.
21. Dale IL, Bradshaw TD, Gesher A and Pettit GR: Comparison of effect of bryostatins and 12-0-tetradecanoylphorbol-13-acetate on protein kinase C activity in A549 human lung carcinoma cells. Cancer Res 49: 3242-3245, 1989.
22. Lilly M, Brown C, Pettit G and Kraft A: Bryostatin 1: a potential anti-leukemic agent for chronic myelomonocytic leukemia. Leukemia 5: 283-287, 1991.
23. Szallasi Z, Krsmanovic L and Blumberg PM: Nonpromoting 12- deoxyphorbol 13-esters inhibit phorbol 12-myristate 13-acetate- induced tumor promotion in CD-I mouse skin. Cancer Res 53: 2507-2512, 1993.
24. EI-Deiry W, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW and Vogelstein B: WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825, 1993.
25. Michieli P, Chedid M, Lin D, Pierce JH, Mercer WE and Givol D: Induction of WAF1/CIP1 by a p53-independent pathway. Cancer Res 54: 3391-3395, 1994.
26. WAF-1 expression by 12-O-tetradeca- noylphorbol-13-acetate in human T cells. Oncogene 22: 5315-5324, 2003.
27. 2/M cell cycle transition. FEBS Lett 444: 32-37, 1999.
28. Iavarone A and Massague J: E2F and histone deacetylase mediate transforming growth factor p repression of cdc25A during keratinocyte cell cycle arrest. Mol Cell Biol 19: 916-922, 1999.
29. 2/M cell cycle transitions: pRb is a critical determinant in blocking DNA replication and preventing endoreduplication. Mol Cell Biol 18: 629-643, 1998.